Evidence map›Paper›PMID 30796681›Full record

ArticleJournal of immigrant and minority health2019

Factors Associated with Virological Rebound in HIV-Positive Sub-Saharan Migrants Living in France After Traveling Back to Their Native Country: ANRS-VIHVO 2006-2009 Study.

Jean-Médard Kankou, Olivier Bouchaud, Nathalie Lele, Marguerite Guiguet, Bruno Spire, Maria Patrizia Carrieri, Sophie Abgrall, ANRS-VIHVO Study Group

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of immigrant and minority health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Jean-Médard KankouAPHP, service de maladies infectieuses et tropicales, Hôpital Avicenne, Bobigny, France.
Olivier BouchaudAPHP, service de maladies infectieuses et tropicales, Hôpital Avicenne, Bobigny, France.
Nathalie LeleAPHP, service de maladies infectieuses et tropicales, Hôpital Avicenne, Bobigny, France.
Marguerite GuiguetUniv Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Université Pierre et Marie Curie, Sorbonne Universités, 75013, Paris, France.
Bruno SpireINSERM U912 (SE4S), Marseille, France.
Maria Patrizia CarrieriINSERM U912 (SE4S), Marseille, France.
Sophie AbgrallAP-HP, Service de Médecine interne/Immunologie clinique, Hôpital Antoine Béclère, 157 rue de la Porte de Trivaux, 92140, Clamart, France. sophie.abgrall@aphp.fr.ORCID http://orcid.org/0000-0002-7891-7594
ANRS-VIHVO Study Group
Inserm · FRUniversité Claude Bernard Lyon 1 · FRSorbonne Université · FRUniversité Paris-Sud · FRUniversité Sorbonne Paris Nord · FR

Funding

ANRS (France Recherche Nord & Sud Sida-HIV Hépatites) ANRS-2005-2
6 · The paper itself

Abstract

In France, around 25% of the estimated number of people living with HIV are migrants, of whom three quarters are from sub-Saharan Africa (SSA). Our objective was to determine factors associated with virological rebound (VR) at the occasion of a transient stay to the country of origin. HIV-positive migrants from SSA participating to the ANRS-VIHVO adherence study between 2006 and 2009, on effective ART with controlled pre-travel HIV-1 plasma viral load (VL), were included. Outcome was VR, defined as VL ≥ 50 copies/ml at the post-travel visit during the week following the return to France. Among 237 persons (61.6% female, median age 41 years (IQR, 35-47), median time on ART 4.2 years (IQR, 2.2-7.1), 27 (11.4%) experienced VR. The main purpose of the travel was to visit family and median time spent abroad was 5.3 weeks (IQR, 4.1-8.8). The travel was extended longer than anticipated by at least 1 week in 42 individuals (17.7%). In multivariable logistic model, risk factors for VR were male sex [adjusted OR (aOR) 5.1; 95% CI 1.6-16.2)], no employment in France (aOR 2.0; 1.2-3.5), self-reported non-adherence during the trip (aOR 14.9; 4.9-45.9) and PI-containing regimen (aOR 4.6; 1.2-17.6). In another analysis not including self-reported adherence, traveling during Ramadan while respecting the fast (aOR 3.3; 1.2-9.6) and extension of the stay (aOR 3.0; 1.1-7.8) were associated with VR. Virological rebound was partly explained by structural barriers to adherence such as extension of the travel and inadequate management of Ramadan fasting. Individuals' journeys should be carefully planned with health care providers.

Indexed as

TravelViral LoadAdultAfrica South of the SaharaAnti-HIV AgentsDrug MonitoringFemaleFranceHIV InfectionsHumansMaleMedication AdherenceMiddle AgedRisk FactorsAnti-HIV AgentsAntiretroviral therapyHIVMigrantSub-Saharan AfricaTravelVirological rebound

Identifiers

PMID30796681
OpenAlexW2915119560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.